Polymorphism of 5,10-methylenetetrahydrofolate reductase (C677T) in patients with antiphospholipid syndrome, its association with cardiovascular lesions

Seheda, Y.; Shevchuk, S.; Kuvikova, I.; Galiutina, O.

Домівка
→
НДІ реабілітації інвалідів
→
Наукові публікації НДІ реабілітації інвалідів
→
Перегляд матеріалів

dc.contributor.author	Seheda, Y.	en
dc.contributor.author	Shevchuk, S.	en
dc.contributor.author	Kuvikova, I.	en
dc.contributor.author	Galiutina, O.	en
dc.date.accessioned	2020-02-11T09:00:31Z
dc.date.available	2020-02-11T09:00:31Z
dc.date.issued	2018
dc.identifier.citation	Polymorphism of 5,10-methylenetetrahydrofolate reductase (C677T) in patients with antiphospholipid syndrome, its association with cardiovascular lesions / Y. Seheda, S. Shevchuk, I. Kuvikova, O. Galiutina // Ann. Rheum. Dis. : first published as 10.1136/annrheumdis-2018-eular. 5232 on 12 June. - 2018. - P. 686.	en
dc.identifier.uri	https://dspace.vnmu.edu.ua/123456789/4340
dc.description.abstract	The present study aimed to analyze the C677T mutation of the MTHFR gene and its association with endothelial dysfunction and clinical manifestations of cardiovascular lesions in APS. 82 patients with APS, including 34 (41.6%) with primary antiphospholipid syndrome (PAPS) and 48 (58.4%) with secondary antiphospholipid syndrome (SAPS) were studied. It was founded that the mutation of the C677T of the MTHFR gene is not a risk factor for the development of atherosclerotic vascular damage in patients with APS, due to the lack of associative interrelationships between the decrease of EDVD, increase of IMT, clinical manifestations on the one hand, and the MTHFR polymorphism on the other.	en
dc.language.iso	en	en
dc.subject	antiphospholipid syndrome	en
dc.subject	polymorphism	en
dc.subject	5,10-methylenetetrahydrofolate reductase	en
dc.subject	cardiovascular lesions	en
dc.title	Polymorphism of 5,10-methylenetetrahydrofolate reductase (C677T) in patients with antiphospholipid syndrome, its association with cardiovascular lesions	en
dc.type	Thesis	en